RxDoctor Payments Data

Steven Nickles, DO

Family Medicine · Ramsey, NJNPI 1760483051

Payments from drug & device makers

$5,197in general payments, 2019–2025

Across 337 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$736
  • AstraZeneca$725
  • Amgen$601
  • AbbVie$370
  • Merck$312
  • Amarin Pharma, Inc.$262
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$5,172100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,197 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$562,905
Medicare patients
550
Services billed
18,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$57,094
JardianceEmpagliflozin54$53,171
JanuviaSitagliptin Phosphate33$44,485
FarxigaDapagliflozin Propanediol27$30,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,618
Janumet XrSitagliptin Phos/Metformin Hcl16$13,301
Breo ElliptaFluticasone/Vilanterol16$9,166
LivaloPitavastatin Calcium11$9,071
LinzessLinaclotide17$9,024
VascepaIcosapent Ethyl14$8,879
Valsartan139$7,346
Dexlansoprazole DrDexlansoprazole16$6,809
ShingrixVaricella-Zoster Ge/As01b/Pf26$5,721
Levothyroxine Sodium467$5,201
Atorvastatin Calcium527$5,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$218$58,52360 claims
MerckJanuvia, Janumet Xr$312$57,78649 claims
Boehringer IngelheimJardiance$251$53,17154 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$736$31,50668 claims
AstraZenecaFarxiga$725$30,47927 claims
AbbVieLinzess, Synthroid$370$12,656102 claims
Kowa Pharmaceuticals America, Inc.Livalo$227$9,07111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$5,201467 claims
Astellas Pharma US IncMyrbetriq$81$3,32011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Ramsey

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →